CAS: 27458-93-1; Isostearyl Alcohol

相似化合物

2724-58-5 68526-85-2 55505-26-5

专利信息

专利号:US-2008032964-A1
优先权日:2006-04-10
标题:Process for the synthesis of azetidinone
发明人：KANSAL VINOD K; AHMAD SUHAIL; MARIAPPAN SHANMUGAVEL; TYAGI BHUPENDRA; PERLMAN NURIT; LE PAIH JACQUES; ZANOTTI-GEROSA ANTONIO
权利人:KANSAL VINOD K; AHMAD SUHAIL; MARIAPPAN SHANMUGAVEL; TYAGI BHUPENDRA; PERLMAN NURIT; LE PAIH JACQUES; ZANOTTI-GEROSA ANTONIO
摘要:Provided are intermediates useful for the synthesis of hydroxyl-alkyl substituted azetidinones, processes of their preparation, and processes for the synthesis of certain hydroxyl-alkyl substituted azetidinones. Also provided are processes for the synthesis of 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone, or ezetimibe.

专利号:US-2014255328-A1
优先权日:2013-03-11
标 题:Hydrothermal Synthesis of Zinc Phlogopite
发明人：MCGUIRE MEAGHAN CLARK; BULL IVOR; JOHNSON GEOFFREY MARK
权利人:BASF SE
摘要:This invention relates to a synthetically derived zinc phlogopite platelets, of superior platelet diameter, effect pigments comprising such synthetically derived platelets and methods of forming said substrates. More specifically the disclosure describes an improved hydrothermal synthesis of zinc phlogopite suitable as a platelets for interference pigments, barrier and flame retardant applications.

专利号:WO-2007094533-A1
优先权日:2006-02-17
标题:Composition for inhibiting collagen degradation and promoting collagen synthesis comprising emodin
发明人：PARK DEOK HOON; LEE JONG SUNG; JUNG EUN SUN; HYUN CHANG GU; HONG SEONG TAEK
权利人:BIOSPECTRUM INC; PARK DEOK HOON; LEE JONG SUNG; JUNG EUN SUN; HYUN CHANG GU; HONG SEONG TAEK
摘要:Disclosed is a composition, comprising emodin, for inhibiting collagen degradation and promoting collagen synthesis. The composition stimulates cell regeneration by promoting the synthesis of collagen by normal fibroblasts, alleviates wrinkles, and imparts the skin with elasticity. Also, the composition can be used as a preparation for external use for skin, such as cosmetics.

专利号:US-2023175032-A1
优先权日:2020-05-13
标 题 :Efficient synthesis of omega-glycosides and alkyl glycosides
发明人：SOETAERT WIM; ROELANTS SOPHIE; STEVENS CHRISTIAN; DELBEKE ELISABETH; LUYTEN GOEDELE; PALA MELIKE; REMMERY JELLE
权利人:AMPHISTAR; UNIV GENT
摘要:The present invention relates to the field of production of novel biosurfactants. More specifically, the present invention relates to the efficient generation of short chained on-glycosides with less than 10%, preferably less than 1%, ω-1 glycosides using a fungal strain such as the yeast Starmerella bombicola having a dysfunctional CYP52M1 cytochrome P450 monooxygenase and a dysfunctional FAO1 fatty alcohol oxidase to produce high amounts of so-called unsaturated (symmetrical) α,ω-bola glycosides free from contaminating α,ω-1 bola glycosides, and subjecting said unsaturated (symmetrical) α,ω-bola glycosides to conditions inducing the breaking of the present double bond(s) such as for example through ozonolysis performed in water. More specifically, the present invention discloses the generation of (acetylated) C9:0 ω-sophoroside aldehydes, C9:0 ω-glucoside aldehydes, C9:0 ω-glucolipids, C9:0 ω-sophorolipids, C9:0 ω-sophoroside alcohols and C9:0 ω-glucoside alcohols and their further derivatives. The present invention also discloses methods to produce alkyl sophorosides in increased ratios.

专利号:US-2008015197-A1
优先权日:2006-06-26
标题 :Process for the preparatrion of zopiclone
发明人：MAINFELD ALEX; MENDELOVICI MARIOARA
权利人:MAINFELD ALEX; MENDELOVICI MARIOARA
摘要:Provided is a process for the preparation of zopiclone, an intermediate in the synthesis of eszopiclone.

专利号:US-10022366-B2
优先权日:2013-04-23
标 题:Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
发明人：STINCHCOMB AUDRA L; GHOSH PRIYANKA
权利人:STINCHCOMB AUDRA L; GHOSH PRIYANKA; UNIV MARYLAND; UNIV KENTUCKY RES FOUND
摘要:Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.